Pregabalin in the treatment of schizophrenic anxiety

Pharmacopsychiatry

Volumn 42, Issue 3, 2009, Pages 124-125

  Schonfeldt Lecuona C ^a   Wolf, R C ^a   Osterfeld, N D ^a   Vasic, N ^a   Connemann, B J ^a   Schmid, M ^a   Freudenmann, R W ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; CLOZAPINE; PREGABALIN; 4 AMINOBUTYRIC ACID; ANTICONVULSIVE AGENT; DRUG DERIVATIVE;

ADULT; ANXIETY DISORDER; AUDITORY HALLUCINATION; CASE REPORT; COMORBIDITY; DAILY LIFE ACTIVITY; DRUG BLOOD LEVEL; FEAR; HUMAN; LETTER; MALE; MENTAL HOSPITAL; PARANOID SCHIZOPHRENIA; PRIORITY JOURNAL; SOCIAL BEHAVIOR; SOCIAL ISOLATION; SCHIZOPHRENIA;

ADULT; ANTICONVULSANTS; ANXIETY DISORDERS; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; SCHIZOPHRENIA;

EID: 68149157983     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0028-1112128     Document Type: Letter

References (17)

1. APA. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, International Version. Washington, DC, American Psychiatric Association ; 1995 ; 279-324
2. Brawek B, Loffler M, Dooley DJ et al. Differential modulation of K(+)- evoked (3) H-neurotransmitter release from human neocortex by gabapentin and pregabalin. Naunyn Schmiedebergs Arch Pharmacol 2008 ; 376 : 301-307
3. Dooley DJ, Donovan CM, Pugsley TA. Stimulus-dependent modulation of [(3) H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther 2000 ; 295 : 1086-1093
4. Feltner DE, Crockatt JG, Dubovsky SJ et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 2003 ; 23 : 240-249
5. Fink K, Dooley DJ, Meder WP et al. Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 2002 ; 42 : 229-236
6. Frampton JE, Foster RH. Pregabalin: in the treatment of generalised anxiety disorder. CNS Drugs 2006 ; 20 : 685 - 693 ; discussion 694-695
7. Gonzalez-Burgos G, Lewis DA. GABA Neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia. Schizophr Bull 2008 ; 34 : 944-961
8. Pande AC, Crockatt JG, Feltner DE et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 2003 ; 160 : 533-540
9. Pande AC, Feltner DE, Jefferson JW et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol 2004 ; 24 : 141-149
10. Regist USF. Schedules of controlled substances: placement of pregabalin into schedule V. Final rule Drug. Enforcement Administration, Department of Justice 2005; Fed Regist 2005 ; 70 (144) : 43633-43635 PMID16050051
11. Rickels K, Pollack MH, Feltner DE et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo- controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 2005 ; 62 : 1022-1030
12. Showraki M. Pregabalin in the treatment of depression. J Psychopharmacol 2007 ; 21 : 883-884
13. Stacey BR, Dworkin RH, Murphy K et al. Pregabalin in the treatment of refractory neuropathic pain: results of a 15-month open-label trial. Pain Med 2008, Mar 11 [Epub ahead of print]
14. Stein DJ, Baldwin DS, Baldinetti F et al. Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies. Eur Neuropsychopharmacol 2008 ; 18 : 422-430
15. Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res 2007 ; 73 : 137-150
16. Woo TU, Shrestha K, Lamb D et al. N-Methyl- d-Aspartate receptor and calbindin-containing neurons in the anterior cingulate cortex in schizophrenia and bipolar disorder. Biol Psychiatry 2008 ; 64 : 803-809
17. Zin CS, Nissen LM, Smith MT et al. An update on the pharmacological management of post-herpetic neuralgia and painful diabetic neuropathy. CNS Drugs 2008 ; 22 : 417-442